Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra).
Keywords: Anakinra; Biologic; COVID-19; IL-1; Treatment.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.